Barclays Sticks to Its Buy Rating for Hims & Hers Health (HIMS)

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Hims & Hers Health, with a price target of $48.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, McKesson, and Cencora. According to TipRanks, Santangelo has an average return of 5.3% and a 52.85% success rate on recommended stocks.

In addition to Barclays, Hims & Hers Health also received a Buy from BTIG’s David Larsen in a report issued on February 19. However, on February 20, Truist Financial maintained a Hold rating on Hims & Hers Health (NYSE: HIMS).

Based on Hims & Hers Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $598.98 million and a net profit of $15.77 million. In comparison, last year the company earned a revenue of $401.56 million and had a net profit of $75.59 million

Based on the recent corporate insider activity of 158 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HIMS in relation to earlier this year. Earlier this month, Oluyemi Okupe, the CFO of HIMS sold 5,262.00 shares for a total of $139,074.66.